Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Gubert Tan

Neurology Mansfield, OH Medical Doctor

NPI 1285621490 CMS profile 542705

222 Marion Ave, Mansfield, OH 44903

Open in the dashboard

General payments

$479

19 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Gubert Tan of Mansfield, OH is reported in the CMS Open Payments database as having received $479 across 19 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 35th percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $246 7
2023 General $56 3
2022 General $135 6
2019 General $42 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Gubert Tan
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Gubert Tan were reported at $246. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Gubert Tan Neurology median Middle half National median
2019 $42 $474 $118–$2,177 $163
2020 $0 $367 $82–$2,309 $114
2021 $0 $438 $104–$2,547 $132
2022 $135 $442 $103–$2,388 $149
2023 $56 $464 $119–$2,312 $160
2024 $0 $468 $119–$2,323 $164
2025 $246 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $156 3 payments
  2. UCB, Inc. $55 2 payments
  3. Horizon Therapeutics plc $48 2 payments
  4. Biogen, Inc. $29 2 payments
  5. Argenx US, Inc. $27 1 payment
  6. Amneal Pharmaceuticals LLC $21 1 payment
  7. SK Life Science, Inc. $21 1 payment
  8. ACADIA Pharmaceuticals Inc $20 1 payment
  9. Xeris Pharmaceuticals, Inc. $20 1 payment
  10. Otsuka America Pharmaceutical, Inc. $18 1 payment
  11. Other $64 4 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $466 18 payments
  2. Education $13 1 payment
Products named General payments · program years 2019–2025
  1. VYALEV $104 1 payment
  2. Fintepla $55 2 payments
  3. UBRELVY $52 2 payments
  4. QULIPTA $52 2 payments
  5. UPLIZNA $48 2 payments
  6. TECFIDERA $29 2 payments
  7. VYVGART $27 1 payment
  8. RYTARY $21 1 payment
  9. NUPLAZID $20 1 payment
  10. GVOKE PFS $20 1 payment
  11. Other $95 6 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 65 drugs

Part D claims

3,273

Median for Neurology: 833

Drug cost

$593,357

Median for Neurology: $202,670

Branded share of claims

20.9%

Median for Neurology: 25.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Avonex (4 Pack) Interferon Beta-1a Brand 13 $108,970
Epidiolex Cannabidiol (Cbd) Brand 13 $87,427
Dimethyl Fumarate Generic 32 $69,221
Aptiom Eslicarbazepine Acetate Brand 37 $51,930
Xcopri Cenobamate Brand 26 $30,567
Rexulti Brexpiprazole Brand 13 $27,177
Glatiramer Acetate Generic 11 $24,035
Neupro Rotigotine Brand 19 $22,800
Eliquis Apixaban Brand 27 $22,464
Briviact Brivaracetam Brand 14 $18,832

The 10 drugs with the highest cost, of 65 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 24 billing codes

Paid by Medicare

$143,639

Medicare's payments for the services billed

Medicare patients

653

Average age 73

Services billed

1,840

347 women, 306 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 56%
Diabetes 36%
Ischemic heart disease 36%
Depression 36%
Chronic kidney disease 30%
Alzheimer's or dementia 24%
Atrial fibrillation 23%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

19 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record